MedImmune and the University of Maryland, Baltimore have entered into a five-year, $6 million research partnership, officials with the biotech firm and school announced Wednesday.
The focus of the research projects includes cardiovascular diseases, oncology and autoimmunity. MedImmune, which is based in Gaithersburg, is expected to contribute at least $5 million; UMB will contribute at least $1 million, according to a news release.
Both will contribute funding and scientists to work on joint research projects and will provide opportunities for scientific exchange and educational training between MedImmune and UMB scientists, students and postdoctoral scholars.
The University of Maryland, College Park and University of Maryland, Baltimore County will also be involved, the news release said.
The Department of Business & Economic Development is expected to provide funding based on what is available during those five years.